Oncoclínicas do Brasil Serviços Médicos S.A. (ONCO3.SA)
- Previous Close
4.7800 - Open
0.0000 - Bid 4.5500 x --
- Ask 4.8400 x --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 9.7200 - Volume
0 - Avg. Volume
5,398,053 - Market Cap (intraday)
3.044B - Beta (5Y Monthly) 0.98
- PE Ratio (TTM)
-- - EPS (TTM)
-1.2700 - Earnings Date Aug 11, 2025 - Aug 15, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.20
Oncoclínicas do Brasil Serviços Médicos S.A. provides healthcare services focused on oncology, hematology, and radiotherapy in Latin America. It offers diagnosis and treatment services, such as pathological analysis, cryotherapy, palliative care, delife, hilotherapy, molecular journey, laser therapy, integrative medicine, myelogram-bone marrow biopsy, OC care line, OC precision medicine, oncoACCESS, survivorship, telemedicine, genetic testing, personalized medicine and individualized treatment, and veinviewer. The company also provides services in the areas of chemotherapy, hormone therapy, molecular target drugs, immunotherapy, bone marrow transplant, catheter salinization and heparinization, and non-oncological infusions. It has collaboration with MGI Tech Co., Ltd. to accelerates the laboratory advancements in genomic medicine. The company was founded in 2010 and is based in São Paulo, Brazil.
www.grupooncoclinicas.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: ONCO3.SA
View MorePerformance Overview: ONCO3.SA
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is IBOVESPA (^BVSP) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ONCO3.SA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ONCO3.SA
View MoreValuation Measures
Market Cap
3.04B
Enterprise Value
6.86B
Trailing P/E
--
Forward P/E
41.15
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.49
Price/Book (mrq)
1.02
Enterprise Value/Revenue
1.10
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-10.38%
Return on Assets (ttm)
-0.69%
Return on Equity (ttm)
-23.67%
Revenue (ttm)
6.23B
Net Income Avi to Common (ttm)
-646.19M
Diluted EPS (ttm)
-1.2700
Balance Sheet and Cash Flow
Total Cash (mrq)
1.92B
Total Debt/Equity (mrq)
165.36%
Levered Free Cash Flow (ttm)
-412.97M